Trial Profile
A Phase II Study of SU011248 in patients with metastatic mucosal or acral/lentiginous melanoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Therapeutic Use
- 16 Oct 2016 Status changed from active, no longer recruiting to completed.
- 08 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
- 19 Jan 2016 Planned End Date changed from 1 Feb 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.